Barclays lowered the firm’s price target on Manhattan Associates (MANH) to $244 from $247 and keeps an Overweight rating on the shares. The company’s Q3 remaining performance obligations were a “tad light” but its outlook implies a strong Q4, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MANH:
- Manhattan Associates upgraded to Equal Weight from Underweight at Morgan Stanley
- Manhattan Associates: Upgraded to Hold Amid Improved Risk/Reward Profile Despite RPO Concerns
- Manhattan Associates Reports Strong Q3 2025 Results
- Manhattan Associates Reports Strong Q3 2025 Financial Results
- Manhattan Associates board replenished share repurchase authority to $100M